Summary
Nasal sprays and subcutaneous injections are the two primary delivery methods for research peptides. This guide compares bioavailability, speed of onset, which peptides suit each method, and the practical differences for regular use.
Two Methods, Different Principles
Research peptides can be delivered to the body through several routes, but two dominate practical use: subcutaneous injection and intranasal spray. Each has genuine advantages — the question is not which is universally superior, but which is appropriate for a specific compound and research objective.
The choice matters more than it might appear. A peptide that reaches its target tissue at high concentration produces the effect you are researching. The same peptide degraded in the gut, stuck at the blood-brain barrier, or administered at the wrong site may produce little measurable response.
How Each Method Works
Subcutaneous Injection
A subcutaneous (SubQ) injection deposits the compound directly into the layer of fatty tissue just beneath the skin. From there, it is absorbed into the capillary network and distributed systemically via the bloodstream.
SubQ injection bypasses the digestive system entirely, which is why peptides (which are broken down by stomach acids and digestive enzymes when taken orally) must be injected or delivered intranasally rather than swallowed.
Bioavailability: Near-complete for most peptides. The compound enters circulation directly from the subcutaneous depot, with degradation occurring primarily after it reaches target tissue rather than during absorption.
Speed of onset: 15–30 minutes for most subcutaneous peptides, depending on vascularity of the injection site and molecular weight of the compound.
Where it excels: Systemic effects — compounds that need to reach peripheral tissue (muscles, tendons, metabolic organs, the immune system). GLP-1 compounds (Retatrutide, Tirzepatide), BPC-157, TB-500, GHK-Cu in vial form, and most bodyweight/metabolic compounds.
Intranasal Spray
The nasal route exploits two distinct pathways:
The olfactory pathway (nose-to-brain): The olfactory epithelium at the top of the nasal cavity connects directly to the olfactory bulb, which is part of the brain. Certain small peptides can travel along the olfactory nerve axons into the central nervous system, bypassing the blood-brain barrier — which would normally block them. This is the mechanism behind nasal oxytocin, nasal vasopressin, and the research into nasal delivery of neuropeptides like Semax and Selank.
Systemic absorption through nasal mucosa: Compounds absorbed through the well-vascularised nasal lining enter the bloodstream directly, similar to sublingual delivery. This pathway is relevant for compounds like Melanotan II and PT-141, which have peripheral receptor targets in addition to central ones.
Bioavailability: Variable and compound-dependent — typically lower than SubQ for systemic targets, but potentially higher than SubQ for CNS targets (where the blood-brain barrier limits what the blood-borne compound can actually deliver to brain tissue).
Speed of onset: Often faster than SubQ for centrally-acting compounds — reported at 5–20 minutes for Semax and Selank.
Head-to-Head Comparison
| Factor | Subcutaneous Injection | Intranasal Spray |
|---|---|---|
| Equipment required | Syringe, needle, alcohol swabs | Spray bottle only |
| Pain / discomfort | Minor (needle insertion) | None |
| Bioavailability (systemic) | High (~95%+) | Moderate (10–40% systemic) |
| CNS delivery | Limited (blood-brain barrier) | High for appropriate peptides (olfactory pathway) |
| Speed of onset | 15–30 minutes | 5–20 minutes (CNS compounds) |
| Consistency of dose | High | Moderate (technique-dependent) |
| Best for | Systemic, metabolic, tissue repair | Cognitive, neurological, some melanocortins |
| Storage requirements | 2–8°C | 2–8°C |
| Travel convenience | Requires sharps, careful packing | No sharps needed |
Which Peptides Suit Each Method
Intranasal — where it has the strongest research support
Semax (FOCUS): A synthetic analogue of ACTH with neuroprotective and nootropic properties. Intranasal delivery was the method used in the original Russian clinical research on Semax — there is extensive institutional evidence for the nasal route specifically.
Selank (CALM): An anxiolytic and nootropic peptide. Like Semax, it was developed and studied specifically for intranasal delivery. The nose-to-brain pathway delivers it to the limbic system with minimal systemic dilution.
DSIP (DREAM): Delta sleep-inducing peptide. Small size and CNS target make intranasal delivery practical and well-supported.
Melanotan II and PT-141 (ATTRACT/MAGNETIZE): Melanocortin receptor agonists. Both have peripheral and central receptor targets. Intranasal delivery has been researched in clinical settings for PT-141 specifically — Palatin Technologies developed an intranasal PT-141 formulation.
GHK-Cu (GLOW): The copper peptide has documented skin and mucosal absorption, with the nasal lining providing direct access to bloodstream for systemic distribution.
Subcutaneous injection — where it remains the better choice
BPC-157: The research showing tissue repair effects was conducted primarily with subcutaneous and intramuscular injection. BPC-157 is a larger peptide that may not cross the nasal mucosa with sufficient efficiency for therapeutic doses.
TB-500: Larger molecular weight; subcutaneous injection is the established research route.
GLP-1 compounds (Retatrutide, Tirzepatide, Semaglutide): These are designed for weekly subcutaneous injection. Their molecular structure is optimised for this route.
MOTS-c and SS-31: Mitochondria-targeting peptides; subcutaneous or intravenous delivery is the researched route.
Technique: Getting the Most from a Nasal Spray
Poor intranasal technique is one of the main reasons researchers report inconsistent results from nasal peptides. A few points that matter:
Blow your nose first: Excess mucus reduces contact between the spray droplets and the absorptive mucosa. A clear nasal passage improves absorption.
Tilt head slightly forward: Counterintuitive, but a slightly forward tilt directs the spray toward the olfactory epithelium at the top of the nasal cavity rather than letting it run down to the throat.
Breathe in gently during spray: A slow nasal inhalation at the moment of spray disperses the droplets upward toward the olfactory epithelium. Forceful inhalation can drive the compound into the sinuses or throat.
Alternate nostrils: Administering in one nostril, then the other for the second pump (if the dose requires two), distributes the compound more evenly.
Hold upright for 1–2 minutes after: Avoid blowing your nose or sniffing forcefully immediately after administration.
The Practical Decision
If you are researching a compound primarily for cognitive, sleep, or neurological effects — Semax, Selank, DSIP, Pinealon — the nasal spray is the method that the research was built around, it requires no needles, and onset is typically faster.
If you are researching a compound for systemic, metabolic, or tissue repair effects — GLP-1 class, BPC-157, TB-500, MOTS-c, SS-31 — subcutaneous injection is the method with the more reliable bioavailability data for those targets.
If you are needle-averse and researching a compound available in both formats, intranasal is a reasonable starting point — provided you understand that for some compounds the systemic dose delivered by spray will be lower than an equivalent SubQ injection.
BioPepTech offers both formats for the compounds where intranasal delivery has research support.
Safety & Regulatory Note
Research peptides are for laboratory use only. Neither delivery method described in this article represents an approved medical treatment. This guide is for educational and research purposes only. Consult a qualified medical professional before using any research compound.
References
- 1.Djupesland PG. (2013). Nasal drug delivery devices: characteristics and performance in a clinical perspective — a review. Drug Delivery and Translational Research, 3(1), 42–62. https://doi.org/10.1007/s13346-012-0108-9
- 2.Illum L. (2000). Transport of drugs from the nasal cavity to the central nervous system. European Journal of Pharmaceutical Sciences, 11(1), 1–18. https://doi.org/10.1016/S0928-0987(00)00087-7
- 3.Chen J, Wang L, Xu H, et al. (2012). Nose-to-brain drug delivery via olfactory pathway. The Journal of Drug Delivery Science and Technology, 22(5), 389–396.
- 4.Usach I, Martinez R, Festini T, Peris JE. (2019). Subcutaneous injection of drugs: literature review of factors influencing pain sensation at the injection site. Journal of Pain Research, 12, 2949–2961. https://doi.org/10.2147/JPR.S200575
- 5.Born J, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL. (2002). Sniffing neuropeptides: a transnasal approach to the human brain. Nature Neuroscience, 5(6), 514–516. https://doi.org/10.1038/nn0602-514
